MondegarAI
← Tracker

Institutional

Kynam Capital Management, LP

CIK 0001907884
$1.62B
Reported AUM
37
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · Kynam Capital Management, LP · Q1 2026

AI · grounded in 13F

Kynam Capital Management, LP closed its position in TYRA for a reduction of $41.1M. The fund also exited positions in CGON and DVAX, totaling $39.3M and $21.2M respectively. On the buy side, the fund established new positions in URGN for $40.4M and LEGN for $28.5M. Additionally, it increased its stake in TVTX by 368%.

Portfolio · Q1 2026

SNDX$188.1MCLDX$185.3MPCVX$169.8MCOGT$155.4MVERA$136.7MBEAM$87.7MTVTXCTMXBCRXVRDNCGEMURGNOther$371.0MKL

Top holdings

QoQ vs Q4 2025

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1SNDXSYNDAX PHARMACEUTICALS INC$17.34-3.77%51.44%18.93%$188.1M11.60%HELD
2CLDXCELLDEX THERAPEUTICS INC NEW$28.62-4.38%34.05%-34.58%$185.3M11.43%102,613−1.7%
3PCVXVAXCYTE INC$47.36-2.87%28.03%118.45%$169.8M10.48%HELD
4COGTCOGENT BIOSCIENCES INC$31.02-5.40%356.18%417.00%$155.4M9.59%2,127,892−34.5%
5VERAVERA THERAPEUTICS INC$32.29-3.27%42.25%79.39%$136.7M8.43%34,827−1.0%
6BEAMBEAM THERAPEUTICS INC$29.40-10.48%58.28%-68.04%$87.7M5.41%+304,971+9.0%
7TVTXTRAVERE THERAPEUTICS INC$45.81-0.80%199.02%233.16%$72.0M4.44%+1,906,034+368.0%
8CTMXCYTOMX THERAPEUTICS INC.$3.00-5.66%13.64%-44.55%$70.6M4.35%+6,047,016+67.4%
9BCRXBIOCRYST PHARMACEUTICALS INC$8.41-0.71%-23.82%-47.83%$54.1M3.34%3,685,731−39.4%
10VRDNVIRIDIAN THERAPEUTICS INC$15.78-4.77%7.49%1.64%$45.8M2.83%+871,111+59.2%
11CGEMCULLINAN THERAPEUTICS INC$13.51-6.38%48.79%-41.08%$44.3M2.73%HELD
12URGNUROGEN PHARMA LTD$26.85-2.72%264.31%73.23%$40.4M2.49%+2,247,393NEW
13KALVKALVISTA PHARMACEUTICALS INC$26.950.00%87.61%33.81%$36.7M2.26%+10,000+0.6%
14APLSUSDAPELLIS PHARMACEUTICALS INC$33.2M2.05%83,607−9.2%
15LEGNLEGEND BIOTECH CORP$32.62-4.62%-6.80%-24.19%$28.5M1.76%+1,576,295NEW
16MBXMBX BIOSCIENCES INC$30.28-2.04%166.31%32.23%$27.9M1.72%HELD
17IMCRIMMUNOCORE HLDGS PLC$28.29-1.63%-24.05%-13.54%$26.7M1.65%+28,475+3.3%
18STROSUTRO BIOPHARMA INC$26.09-9.03%206.94%-84.68%$21.7M1.34%+392,968+81.9%
19RVMDREVOLUTION MEDICINES INC$149.23-4.15%263.18%421.05%$20.2M1.24%+207,500NEW
20BNRBURNING ROCK BIOTECH LTD$9.210.55%217.59%-95.96%$19.8M1.22%+232,672+23.4%
21SLNOSOLENO THERAPEUTICS INC$53.010.00%-29.80%288.35%$18.7M1.16%+560,000NEW
22NRIXNURIX THERAPEUTICS INC$14.64-4.19%14.55%-52.37%$18.5M1.14%775,600−39.4%
23PHVSPHARVARIS N V$31.09-1.71%85.28%74.96%$18.1M1.12%HELD
24EVMNEVOMMUNE INC$19.92-3.72%8.20%16.36%$14.4M0.89%+440,014+237.2%
25RLAYRELAY THERAPEUTICS INC$13.52-7.02%302.38%-58.32%$14.2M0.87%HELD
26GERNGERON CORP$1.17-3.31%-26.88%-4.10%$10.2M0.63%+3,380,000+97.8%
27ENGENE HOLDINGS INC$9.2M0.57%136,055−9.1%
28DSGNDESIGN THERAPEUTICS INC$10.65-1.02%165.59%-31.20%$8.3M0.51%HELD
29WVEWAVE LIFE SCIENCES LTD$5.73-5.91%-20.64%3.99%$7.0M0.43%1,203,912−55.5%
30CLYMCLIMB BIO INC$10.55-3.30%658.99%-41.32%$6.9M0.42%25,000−2.4%
31AMRNAMARIN CORP PLC$13.930.94%$6.8M0.42%+83,109+21.3%
32BHVNBIOHAVEN LTD$10.80-5.26%$5.9M0.37%HELD
33PRLDPRELUDE THERAPEUTICS INC$3.81-6.62%$5.4M0.34%+803,684+101.9%
34CRBUCARIBOU BIOSCIENCES INC$1.92-7.02%$4.8M0.29%HELD
35ALECALECTOR INC$1.63-9.67%$4.3M0.27%HELD
36PRQRPROQR THRAPEUTICS N V$1.50-1.96%$2.5M0.16%HELD
37CADLCANDEL THERAPEUTICS INC$8.51-8.20%$980K0.06%+200,000NEW
38TYRATYRA BIOSCIENCES INC$26.64-1.99%1,564,492EXITED
39CGONCG ONCOLOGY INC$53.72-4.23%945,830EXITED
40DVAXDYNAVAX TECHNOLOGIES CORP1,375,632EXITED
41OMEROMEROS CORP$9.79-4.49%200,000EXITED

Source: SEC EDGAR · accession 0001907884-26-000007. 13F discloses long positions only — shorts, foreign equities, and options are excluded.